دورية أكاديمية
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
| العنوان: | Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey |
|---|---|
| المؤلفون: | Doesum, Jaap van, Salmanton-García, Jon, Marchesi, Francesco, Blasi, Roberta di, Falces-Romero, Iker, Cabirta, Alba, Farina, Francesca, Besson, Caroline, Weinbergerová, Barbora, Praet, Jens van, Schönlein, Martin, López-García, Alberto, Lamure, Sylvain, Guidetti, Anna, Ramón, Cristina de, Batinić, Josip, Gavriilaki, Eleni, Tragiannidis, Athanasios, Tisi, Maria Chiara, Plantefeve, Gaëtan, Petzer, Verena, Ormazabal-Vélez, Irati, Marques de Almedia, Joyce, Marchetti, Monia, Maertens, Johan, Machado, Marina, Kulasekararaj, Austin G., Hernández-Rivas, José Ángel, Gomes Da Silva, María, Fernández, Noemí, Espigado, Ildefonso, Drgona, Lubos, Dragonetti, Giulia, Metafuni, Elisabetta, Calbacho, María, Blennow, Ola, Wolf, Dominik, Anrooij, Bjorn van, Nunes-Rodrigues, Raquel, Nordlander, Anna, Martín-González, Juan-Alberto, Lievin, Raphaël, Jiménez, Moraima, Gräfe, Stefanie, García-Sanz, Ramón, Córdoba, Raúl, Rahimli, Laman, Meerten, Tom van, Cornely, Oliver A., Pagano, Livio |
| بيانات النشر: | American Society of Hematology |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Clinical Trials and Observations, Lymphoid Neoplasia, Myeloid Neoplasia, Transplantation |
| الوصف: | Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19–caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| العلاقة: | Publisher's version; The underlying dataset has been published as supplementary material of the article in the publisher platform at 10.1182/bloodadvances.2022009578; http://dx.doi.org/10.1182/bloodadvances.2022009578Test; Sí; e-issn: 2473-9529; Blood Advances 7(11): 2645-2655 (2023); http://hdl.handle.net/10261/347609Test |
| DOI: | 10.1182/bloodadvances.2022009578 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2022009578Test http://hdl.handle.net/10261/347609Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.40EA941F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/bloodadvances.2022009578 |
|---|